Francesco Galimi

TL;DR: Ciardiello et al. as discussed by the authors found that HER2 amplification was a predictor of resistance to anti-epidermal growth factor receptor (EGFR) antibodies and response to combination therapies against HER2 in this tumor setting.

TL;DR: The role of MET in mediating primary and secondary resistance to anti-EGFR therapies in colorectal cancer is highlighted and the use of MET inhibitors in patients displaying resistance as a result of MET amplification is encouraged.

TL;DR: It is shown that MEK inhibition results in MYC-dependent transcriptional upregulation of ERBB3, which is responsible for intrinsic drug resistance, and this data suggest a combination strategy for treating KRAS mutant colon and lung cancers and a way to identify the tumors that are most likely to benefit from such combinatorial treatment.

TL;DR: Preclinical rationale for clinical trials targeting HER2 activating mutations in metastatic colorectal cancer is provided, and PDXs with HER2 mutations show durable tumor regression when treated with dual HER2-targeted therapy.

TL;DR: Five CRC intrinsic subtypes (CRIS) endowed with distinctive molecular, functional and phenotypic peculiarities successfully categorize independent sets of primary and metastatic CRCs, with limited overlap on existing transcriptional classes and unprecedented predictive and prognostic performances.